Abstract
The genomic revolution has advanced our understanding of breast cancer biology and the molecular basis of antitumor immunity. Trastuzumab, the first monoclonal antibody for breast cancer, is now a routine part of clinical care. Breast cancer vaccines may be more effective by actively recruiting both humoral and cellular immunity to the therapeutic effort. However, immunization alone is unlikely to have significant activity against established breast cancers, where it is limited by potent mechanisms of immune tolerance and the immunobiology of breast cancer itself. The next generation of clinical studies should integrate breast cancer vaccines with standard breast cancer drugs or novel immunotherapeutics in strategic doses and schedules that abrogate immune tolerance and groom the tumor microenvironment for a productive immune response.
Original language | English (US) |
---|---|
Pages (from-to) | 831-841 |
Number of pages | 11 |
Journal | Expert review of vaccines |
Volume | 4 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2005 |
Keywords
- Breast cancer
- Cancer vaccines
- Combinatorial immunotherapy
- Immune modulation
- Immune tolerance
ASJC Scopus subject areas
- Immunology
- Molecular Medicine
- Pharmacology
- Drug Discovery